Subscribe to Search results

BPL Factor 8 concentrate (Batch 1227), approved for clinical use on 29 September 1976, had a product label which noted that: "less than 1500 plasma donations used in the preparation of this batch".

Published on:

BPL Factor 8 concentrate (Batch 1237) was approved for clinical use. The product label noted that: "less than 1500 plasma donations used in the preparation of this batch".

Published on:

Dried Factor 8 Fraction from BPL (Batch 8 CRV 22344) was approved for clinical use. The product label noted that: "less than 7500 plasma donations used in the preparation of this batch".

Published on:

Dried Factor 8 Fraction from BPL (Batch 8Y 3607) was approved for clinical use. The product label noted that: "the preparation is of human origin. It has been heat treated, in the vial, to reduce the risk of infection by viral agents (including hepatitis and AIDS viruses) but it cannot be assumed to be free from the risk of transmission of viral infections."

Published on:

Dried Factor 8 Fraction heat-treated from BPL noted on its label that: "this product prepared from human venous plasma, is heat-treated in its final container to reduce the risk of viral infections (including HIV and hepatitis) but freedom from this risk cannot be assumed."

Published on:

In June 1985, a document about the BPL (specifically background and current information) about the facility was produced for members of the CBLA. It detailed its product list, manufacturing targets, revenue and its position on self-sufficiency and meeting the demand for plasma, amongst other topics.

Published on:

The product labels for BPL Factor 8 concentrate in March 1976 noted: "less than 1500 plasma donations used in the preparation of this batch".

Published on:

Dr Lane wrote to Thomas Dutton, of the DHSS, enclosing a paper on the requirement for hepatitis testing at BPL, in relation to the stop-gap provisions for plasma fractionation at BPL. He said the paper was to enable Mr Dutton to see what he thought about this matter prior to planned discussions with Dr Waiter and Dr Maycock at DHSS.

Published on:

A note of a discussion held at the DHSS (in January 1978) regarding RIA testing to contain hepatitis at BPL recorded agreement that Dr Lane would revise his paper to include information about the additional staff, accommodation and costs necessary to introduce RIA at BPL, and that this would be shown to the Medicines Division.

Published on:

Dr Lane wrote a letter to Professor Mollison enclosing the paper submitted to DHSS on "Stop Gap Provision for Plasma Fractionation at BPL". The paper outlined the problems of containing hepatitis in the preparation of concentrates and the programme to provide radioimmunoassay service to contain Hepatitis B.

Published on:

A report to the Advisory Sub-committee on Blood Products and Blood Group Reference Laboratories of the Central Committee of the National Blood Transfusion Service was published.

Published on:

Dr Lane wrote a letter to Dr Jones concerning the difference in pool sizes between commercial and non-commercial concentrate products.

Published on:

The Protein Fractionation Technology Working Party published a report advising that, in order to reduce the need for purchasing overseas blood products, BPL needed to produce 450,000 litres of plasma annually.

Published on:

The Advisory Group on Testing For the Presence of Hepatitis B Surface Antigen and Its Antibody published its third draft report.

Published on:

The UK Haemophilia Centre Directors Hepatitis Working Party convened to discuss hepatitis surveillance, chronic hepatitis, and prospective studies and trials.

Published on:

The Second Annual Report on Project Number J/S240/78/7 was published, detailing the findings from studies of the epidemiology and chronic sequelae of Factor 8 and 9 associated hepatitis in the United Kingdom.

Published on:

Dr Craske sent a letter to Dr Walford enclosing a draft letter intended to be published in The Lancet, detailing the situation relating to the risk of NANBH after first exposure to Factor 8.

Published on:

The Working Party on Plasma Supply published a draft report: 'A Comparison of Freeze-Dried Cryoprecipitate and Intermediate Purity Concentrates As Major Products For National Cell Sufficiency in Factor VIII'.

Published on:

Dr Bidwell sent a memo to Dr Lane confirming that PFL labelling would change to reflect that Factor 8 made at PFL would come from a pool size of up to 5,000 donations.

Published on:

Dr Snape sent a memo to Peter Prince advising that an extension to a maximum pool size of 20,000 donations would be contained in any future product licensing applications.

Published on: